STOCK TITAN

Ideaya Biosciences - IDYA STOCK NEWS

Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.

Overview of IDEAYA Biosciences

IDEAYA Biosciences Inc. (IDYA) is a precision medicine oncology company that specializes in discovering and developing targeted therapeutics for genetically defined patient populations. By leveraging advanced molecular diagnostics and synthetic lethality, the company identifies cancer vulnerabilities and develops small molecule therapies aimed at interfering with DNA damage repair and tumor microenvironment interactions. IDEAYA operates at the intersection of drug discovery and translational biomarker validation, positioning itself as a key entity in the evolving field of precision medicine.

Core Business Areas and Approach

IDEAYA’s core business is built on its unique approach to oncology drug discovery. The company focuses on:

  • Synthetic Lethality: Exploiting vulnerabilities in the DNA damage and repair mechanisms specific to certain tumor genotypes, thereby enabling targeted therapeutic interventions.
  • Precision Medicine: Utilizing molecular diagnostics and translational biomarkers to select patients most likely to benefit from its therapies, ensuring personalized treatment strategies.
  • Innovative Drug Discovery: Integrating small molecule discovery with advanced computational methodologies and physics-based approaches to unravel previously undruggable targets.

Market Position and Differentiation

IDEAYA stands out in the competitive oncology landscape due to its robust drug discovery process and its strategic focus on precision therapies. The company has assembled a world-class team of scientists and advisors, including Nobel laureates and national academy members, which underscores its deep expertise and authority in the biotech industry. Furthermore, its collaborations with industry giants and academic partners boost its R&D capabilities and enhance its credibility in developing transformative therapeutic candidates.

Clinical Pipeline and Strategic Collaborations

IDEAYA’s extensive clinical-stage pipeline addresses multiple oncology targets using innovative mechanisms. Its product candidates are designed to exploit synthetic lethality in various biomarker-defined patient groups. The company is actively advancing candidates that target key proteins and enzymes involved in tumor DNA repair and epigenetic regulation. Strategic collaborations with leading pharmaceutical companies not only share the risk and cost of development but also provide access to advanced research and regulatory expertise.

Scientific and Operational Excellence

Backed by a solid foundation of scientific research and rigorous due diligence during drug development, IDEAYA demonstrates a commitment to operational excellence. Its integrated approach couples pioneering laboratory research with state-of-the-art computational methods, ensuring that its innovative candidates are robustly validated preclinically before entering clinical trials. This methodical process helps build trust among stakeholders and supports its long-term potential as an innovator in precision oncology.

Implications in Precision Oncology

Through its focus on genetically defined patient populations, IDEAYA addresses an unmet need in the treatment of cancers with specific molecular profiles. Investors, analysts, and industry experts find value in understanding how the company’s unique focus on synthetic lethality and translational biomarker development may offer differentiated outcomes compared to traditional approaches. The company’s rigorous, data-driven methodology provides clear insights into the complex dynamics of oncogenic pathways, reinforcing its reputation as a knowledgeable and respected player in the biotech community.

Conclusion

In summary, IDEAYA Biosciences exemplifies a next-generation precision medicine approach in oncology. With its strategically developed pipeline, strong scientific foundation, and collaborative industry partnerships, the company is well positioned to contribute meaningfully to advancements in targeted cancer therapeutics, fostering better patient outcomes through innovative science and technology.

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) has announced its participation in two upcoming investor relations events in April 2025. The company will participate in:

  • The 2025 RBCCM Ophthalmology Conference on April 3rd, 2025 at 11:30 AM ET, featuring a fireside chat with CEO Yujiro S. Hata and CMO Darrin Beaupre
  • The Stifel 2025 Virtual Targeted Oncology Forum on April 8th, 2025 at 12:00 PM ET, featuring CEO Yujiro S. Hata

Live audio webcasts will be available on the company's investor relations website, with replays accessible for 30 days after the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) has received FDA Breakthrough Therapy Designation (BTD) for darovasertib, a first-in-class protein kinase C inhibitor, for neoadjuvant treatment of adult patients with primary uveal melanoma (UM) recommended for enucleation.

The BTD application was supported by Phase 2 clinical data showing 82% ocular tumor shrinkage rate and 61% eye preservation rate in UM patients. The company plans to initiate a Phase 3 registrational study in neoadjuvant UM in H1 2025.

Neoadjuvant UM represents a significant market opportunity with approximately 12,000 annual patients across North America, Europe, and Australia, with no FDA-approved systemic therapies currently available. The company plans to present updated clinical data, including efficacy, safety, and vision preservation metrics, at medical conferences in mid-2025 and H2 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of inducement stock options to a new employee on March 27, 2025. The Compensation Committee approved non-qualified stock options to purchase 17,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options were granted at an exercise price of $17.43 per share, matching the closing price of IDEAYA's stock on the Nasdaq Global Select Market on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly installments over the following three years, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
none
Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) announced multiple presentations at AACR 2025, featuring IDE275 (GSK959), their Phase 1 Werner Helicase inhibitor. The drug, developed in partnership with GSK, will be highlighted in an oral presentation and three poster presentations.

IDE275 has shown potential as a best-in-class WRN inhibitor for treating MSI-H solid tumors, demonstrating selective preclinical efficacy. The drug targets significant patient populations, with MSI-H prevalence reported at approximately 31% in endometrial, 20% in colorectal, and 19% in gastric cancers.

Under the collaboration terms, GSK holds exclusive global rights and covers 80% of R&D costs, while IDEAYA maintains 20%. IDEAYA could receive a $10M milestone payment upon Phase 1 expansion, up to $465M in development milestones, and up to $475M in commercial milestones, plus 50% of U.S. net profits and tiered royalties on global non-U.S. sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) has announced a research collaboration with ATTMOS to enhance its drug discovery capabilities for first-in-class oncology targets. The partnership aims to develop a physics-based computational platform for small molecule discovery, focusing on targets currently considered undruggable.

The collaboration will combine IDEAYA's expertise in structural biology and pharmaceutical drug discovery with ATTMOS's capabilities in computational chemistry, high-performance computing, and software development. The primary goal is to create a workflow solution for high-throughput absolute binding free energy perturbation predictions (ABFEP) of drug candidate molecules.

The initiative will utilize the Amber molecular dynamics suite for GPU-accelerated free energy simulations. IDEAYA will leverage its wet-lab drug discovery campaign data to train and evaluate ABFEP-based active learning cycles, enabling efficient screening of chemical libraries for novel small molecule ligands.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
AI
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of non-qualified stock options to four newly hired employees through its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved options to purchase 125,600 shares of common stock on February 27, 2025.

The stock options were granted at an exercise price of $20.24 per share, matching the closing price of IDEAYA's stock on the Nasdaq Global Select Market on the grant date. These options come with a 10-year term and follow a four-year vesting schedule: 25% vesting after the first year, with the remaining 75% vesting in equal monthly installments over the following three years. The vesting is contingent upon continued employment with IDEAYA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
Rhea-AI Summary

IDEAYA Biosciences reported its Q4 and full-year 2024 financial results, highlighting significant progress across its clinical pipeline. The company ended 2024 with approximately $1.1 billion in cash, cash equivalents, and marketable securities, expected to fund operations into at least 2028.

Key developments include over 230 patients enrolled in the registration-enabling trial for darovasertib in metastatic uveal melanoma, with median PFS readout targeted by year-end 2025. The company reported encouraging Phase 1 expansion results for IDE397 in MTAP-deletion cancers and selected clinical expansion doses for DLL3 TOP1i ADC IDE849.

Financial highlights for Q4 2024 include collaboration revenue of $7.0 million, R&D expenses of $140.2 million, and a net loss of $130.3 million. The full-year 2024 net loss was $274.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences (IDYA) has expanded its clinical collaboration with Gilead Sciences to evaluate IDE397, a potential first-in-class MAT2A inhibitor, in combination with Gilead's Trodelvy in MTAP-deletion non-small cell lung cancer (NSCLC). The combination targets two distinct mechanisms in MTAP-deletion solid tumors, with MTAP-deletion occurring in approximately 15% of NSCLC cases, representing a significant portion of the estimated 48,000 U.S. cases annually.

The study will expand the ongoing Phase 1 trial, which currently evaluates the combination in MTAP-deletion urothelial cancer. Under the agreement, both companies retain commercial rights to their respective compounds. IDEAYA will sponsor the study while Gilead provides Trodelvy supply. The company expects to provide clinical program updates in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) has appointed Joshua Bleharski, Ph.D. as Chief Financial Officer, expected to transition into the role by early May. Dr. Bleharski joins from J.P. Morgan, where he served as Managing Director and Global Co-Head of Biopharma in the Healthcare Investment Banking group for nearly 17 years.

During his tenure at J.P. Morgan, Dr. Bleharski advised on financing and strategic transactions exceeding $65 billion in value for biotechnology companies. The company currently has 6 potential first-in-class clinical programs and 3 preclinical programs in development across multiple solid tumor indications.

Dr. Bleharski's background includes positions as Senior Staff Scientist at a private biotechnology company and post-doctoral fellowships at LIAI and UCLA School of Medicine. He holds a BS in Biology from Duke University, a Ph.D. in Immunology from UCLA, and an MBA from UC Berkeley's Haas School of Business.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
management
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) has announced the grant of non-qualified stock options to two newly hired employees. The Compensation Committee approved options to purchase 62,800 shares of common stock on January 30, 2025, under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options were granted at an exercise price of $23.88 per share, matching IDEAYA's closing price on The Nasdaq Global Select Market on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none

FAQ

What is the current stock price of Ideaya Biosciences (IDYA)?

The current stock price of Ideaya Biosciences (IDYA) is $14.77 as of April 1, 2025.

What is the market cap of Ideaya Biosciences (IDYA)?

The market cap of Ideaya Biosciences (IDYA) is approximately 1.3B.

What is the primary focus of IDEAYA Biosciences?

IDEAYA Biosciences focuses on precision medicine in oncology, using synthetic lethality and molecular diagnostics to develop targeted therapeutics for genetically defined patient populations.

How does IDEAYA differentiate itself in the oncology market?

IDEAYA differentiates itself by integrating advanced small molecule drug discovery with translational biomarker validation, supported by a world-class scientific team and strategic collaborations with major industry partners.

Which innovative approaches does IDEAYA employ in its drug development?

The company utilizes a combination of synthetic lethality, computational drug discovery, and high-throughput screening methods to identify and develop therapies that target specific cancer vulnerabilities.

What types of diseases are targeted by IDEAYA's therapeutics?

IDEAYA targets various oncological conditions, focusing on tumors defined by genetic mutations and molecular signatures related to DNA damage and repair mechanisms.

How does IDEAYA ensure that its therapies reach the right patient populations?

By employing molecular diagnostics and translational biomarker strategies, IDEAYA selects patient populations that are most likely to benefit from its targeted therapies, ensuring a precision medicine approach.

What role do strategic partnerships play for IDEAYA?

Strategic partnerships with leading pharmaceutical companies and academic institutions enhance IDEAYA’s research capabilities, support its clinical development, and help in mitigating risks associated with drug discovery.

Can you explain the term 'synthetic lethality' in the context of IDEAYA's work?

Synthetic lethality refers to targeting cancer-specific vulnerabilities by inhibiting compensatory pathways in tumor cells, a strategy that IDEAYA applies to develop therapies for patients with certain genetic profiles.

How does IDEAYA contribute to advancements in precision oncology?

IDEAYA contributes by leveraging its deep scientific expertise and novel drug discovery approaches, developing innovative therapies that address unique oncogenic mechanisms, thus potentially improving patient outcomes.
Ideaya Biosciences

Nasdaq:IDYA

IDYA Rankings

IDYA Stock Data

1.30B
86.63M
1.04%
109.56%
10.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO